Previous studies have shown that IDH mutations led to better clinical outcomes and a longer median 2-year survival in GBM (IDH wild-type: 15 months; IDH mutant: 31 months) and anaplastic astrocytoma (IDH wild-type: 20 months; IDH mutant: 65 months)27. The gene discussed is IDH1; the disease is glioblastoma.